An FDA advisory committee voted 6-4 against expanding approved indications for liposomal bupivicaine for regional pain control after surgery.  This drug is a central element in many institutions' Enhanced Recovery After Surgery programs.  They cited inconsistent results, failure to provide comparative results, and increased deaths associated with the drug.  The official FDA will use this assessment as part of their deliberations.